PULSE BIOSCIENCES (PLSE) COO Liane Teplitsky Receives RSU Award

What Happened

• Liane Rae Teplitsky, Chief Operating Officer of Pulse Biosciences (PLSE), was granted two Restricted Stock Unit (RSU) awards on August 8, 2026: 200,000 RSUs and 700,000 RSUs (total 900,000 RSUs). Each RSU is a contingent right to one share; the awards are recorded at $0.00 because no shares were issued or cash exchanged at grant. These are grants (transaction code A), not open‑market purchases or sales.

Key Details

• Transaction date: 2026-08-08; filing date: 2026-08-28 (the Form 4 filing is later than the typical 2‑business‑day reporting window).
• Award amounts: 200,000 RSUs and 700,000 RSUs (total 900,000 RSUs); reported at $0.00 (derivative award).
• Shares owned after transaction: not specified in the provided filing.
• Notable footnotes:
  • F1: Each RSU represents a contingent right to receive one share of common stock upon vesting.
  • F2: RSUs vest only upon satisfaction of performance‑based criteria set by the Board.
  • F3: Vesting structure (as described) — two sevenths of the award vest in equal installments on the 1st, 2nd, 3rd and 4th anniversaries of the grant date; the remaining shares vest in tranches upon achievement of three performance criteria tied to market capitalization ($2B–$5B) and GAAP product revenue ($100M–$330M), subject to continued service through each milestone.

Context

• RSUs are derivative awards that convert into shares only after vesting; they do not represent immediately tradable stock or cash proceeds. Because these RSUs are performance‑based and service‑conditioned, they are primarily retention/incentive compensation rather than immediate insider buying or selling. The delayed filing reduces the timeliness of public disclosure; investors should watch future filings and proxy statements for vesting events and updated insider holdings.